Free Trial
NASDAQ:ACET

Adicet Bio Q4 2023 Earnings Report

Adicet Bio logo
$0.70 -0.05 (-6.59%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$0.72 +0.02 (+2.86%)
As of 05/21/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adicet Bio EPS Results

Actual EPS
-$0.69
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Adicet Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adicet Bio Announcement Details

Quarter
Q4 2023
Time
Q4 2023 Earnings Release
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
8:00AM ET

Adicet Bio Earnings Headlines

Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
See More Adicet Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email.

About Adicet Bio

Adicet Bio (NASDAQ:ACET), a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

View Adicet Bio Profile

More Earnings Resources from MarketBeat